سعر Sigmalip 40mg tab 2026

Sigmalip 40 mg is an Egyptian atorvastatin 40 mg film-coated tablet product by Sigma Pharmaceutical Industries (pack size not stated by the source row); atorvastatin is an HMG-CoA reductase inhibitor (statin) lipid-lowering agent.

• Adjunct to diet to reduce elevated total-C, LDL-C, apolipoprotein B and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia (including heterozygous familial) or combined (mixed) hyperlipidaemia when diet and other non-drug measures are inadequate.Population: Adults and children aged 10 years and olderelectronic medicines compendium (eMC)
• Reduction of total-C and LDL-C in adults with homozygous familial hypercholesterolaemia, as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.Population: Adultselectronic medicines compendium (eMC)
• Prevention of cardiovascular events in adults estimated to have a high risk of a first cardiovascular event, as an adjunct to correction of other risk factors.Population: Adultselectronic medicines compendium (eMC)

• Common: nasopharyngitis, allergic reactions, hyperglycaemia, headache, pharyngolaryngeal pain, epistaxis, constipation, flatulence, dyspepsia, nausea, diarrhoea, myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain, abnormal liver function tests and increased CK.International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity to atorvastatin or any excipient; active liver disease or unexplained persistent transaminase elevations above 3 x ULN; pregnancy, breast-feeding and women of child-bearing potential not using appropriate contraception; treatment with glecaprevir/pibrentasvir.International label, same formulation · electronic medicines compendium (eMC)
• Acute liver failure or decompensated cirrhosis; hypersensitivity to atorvastatin or any excipient (anaphylaxis, angioneurotic oedema, erythema multiforme, SJS and TEN reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Skeletal muscle: myalgia, myositis and myopathy that may progress to rhabdomyolysis; very rare immune-mediated necrotising myopathy; measure CK before treatment in patients with predisposing factors (renal impairment, hypothyroidism, hereditary muscle disorders, previous statin/fibrate muscle toxicity, liver disease/alcohol, age over 70).International label, same formulation · electronic medicines compendium (eMC)
• Liver function tests before initiation and periodically thereafter; reduce dose or withdraw if transaminases above 3 x ULN persist; caution with substantial alcohol consumption or history of liver disease.International label, same formulation · electronic medicines compendium (eMC)
• Statins may raise blood glucose; monitor patients at risk of diabetes; interstitial lung disease reported rarely; myasthenia gravis may be induced or aggravated; contains lactose.International label, same formulation · electronic medicines compendium (eMC)

• Strong CYP3A4 inhibitors / OATP1B1 inhibitors (e.g. clarithromycin, itraconazole, HIV protease inhibitors, ciclosporin)Increase atorvastatin plasma concentrations and the risk of myopathy; avoid where possible or use the lowest dose with monitoring.electronic medicines compendium (eMC)
• Systemic fusidic acidRisk of myopathy including rhabdomyolysis (some fatal); atorvastatin should be suspended during systemic fusidic acid treatment.electronic medicines compendium (eMC)
• Elbasvir/grazoprevir; letermovirAtorvastatin dose should not exceed 20 mg/day; atorvastatin is not recommended with letermovir plus ciclosporin.electronic medicines compendium (eMC)

• Contraindicated in pregnancy; safety not established; rare reports of congenital anomalies after intrauterine statin exposure; should not be used by women who are pregnant, trying to become pregnant or suspect pregnancy; suspend for the duration of pregnancy.International label, same formulation · electronic medicines compendium (eMC)
• Discontinue when pregnancy is recognised, or consider the ongoing therapeutic needs of the individual patient; may cause fetal harm based on the mechanism of action; treatment of hyperlipidaemia is not generally necessary during pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Contraindicated during breast-feeding; unknown whether excreted in human milk (similar plasma and milk concentrations in rats).International label, same formulation · electronic medicines compendium (eMC)

• Atorvastatin: Selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis; lowers plasma cholesterol and increases hepatic LDL receptors, enhancing LDL uptake and catabolism.